Non–high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease  Yoshiki Nishizawa,

Slides:



Advertisements
Similar presentations
Volume 62, Issue 6, Pages (December 2002)
Advertisements

LDL cholesterol in CKD—to treat or not to treat?
Associations Between Low Serum Testosterone and All-Cause Mortality and Infection- Related Hospitalization in Male Hemodialysis Patients: A Prospective.
Beta blockers in the management of chronic kidney disease
Volume 70, Issue 3, Pages (August 2006)
FGF-23 in patients with end-stage renal disease on hemodialysis
Anemia management in chronic kidney disease
Lipopheresis in the nephrotic syndrome
Volume 55, Issue 2, Pages (February 1999)
II. assessment of dyslipidemias
Progression of renal failure and hypertensive nephrosclerosis
Volume 63, Pages S88-S90 (June 2003)
C-reactive protein and dialysis access
Burden of chronic kidney disease: North Africa
Susumu Takahashi, Kazuyoshi Okada, Mitsuru Yanai  Kidney International 
Volume 70, Pages S21-S25 (December 2006)
Volume 66, Issue 3, Pages (September 2004)
George A. Kaysen, Burl R. Don
Volume 63, Issue 2, Pages (February 2003)
Altered Serum n-6 Polyunsaturated Fatty Acid Profile and Risks of Mortality and Cardiovascular Events in a Cohort of Hemodialysis Patients  Yukinobu Kuwamura,
Comorbidity and confounding in end-stage renal disease
Per-Ola Attman, M.D, Petar Alaupovic, Ola Samuelsson 
Volume 64, Issue 1, Pages (July 2003)
Volume 70, Issue 11, Pages (December 2006)
Volume 65, Issue 2, Pages (February 2004)
Volume 68, Issue 1, Pages (July 2005)
Edmund G. Lowrie  Kidney International 
Study of Heart and Renal Protection (SHARP)
LDL cholesterol in CKD—to treat or not to treat?
Volume 70, Issue 12, Pages (December 2006)
Anemia as a risk factor for cardiovascular disease
Blood pressure targets in hemodialysis patients
FGF-23 in patients with end-stage renal disease on hemodialysis
Volume 63, Pages S115-S118 (June 2003)
New insights in uremic toxins
Volume 61, Issue 2, Pages (February 2002)
AGEs in foods: Do they play a role in uremia?
Volume 87, Issue 1, Pages (January 2015)
Volume 67, Issue 4, Pages (April 2005)
Volume 68, Issue 2, Pages (August 2005)
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Volume 67, Issue 5, Pages (May 2005)
Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6?  Peter Stenvinkel, Peter Barany, Olof Heimbürger, Roberto Pecoits-Filho,
Homocysteine, renal function, and risk of cardiovascular disease
Volume 63, Issue 2, Pages (February 2003)
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients  B. Bammens, P. Evenepoel, H. Keuleers,
Peritoneal dialysis in Mexico
Kathy E. Sietsema, Antonino Amato, Sharon G. Adler, Eric P. Brass 
Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program  Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.
Current status of maintenance hemodialysis in Beijing, China
Low triiodothyronine and survival in end-stage renal disease
Volume 72, Issue 2, Pages (July 2007)
Charles A. Herzog  Kidney International 
Fetuin-A is not associated with mortality in chronic kidney disease
Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa 
Douglas E. Schaubel, Howard I. Morrison, Stanley S.A. Fenton 
Volume 75, Issue 7, Pages (April 2009)
Volume 64, Issue 4, Pages (October 2003)
Volume 64, Issue 3, Pages (September 2003)
III. Treating dyslipidemias
Volume 70, Issue 10, Pages (November 2006)
Ralf Dikow, Marcin Adamczak, Daniel Ernesto Henriquez, Eberhard Ritz
Volume 67, Issue 6, Pages (June 2005)
Volume 53, Issue 5, Pages (May 1998)
Volume 63, Issue 5, Pages (May 2003)
Volume 61, Issue 6, Pages (June 2002)
Lipoprotein abnormalities in diabetic nephropathy
Volume 57, Pages S44-S48 (April 2000)
Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease?  Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger  Kidney.
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Presentation transcript:

Non–high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease  Yoshiki Nishizawa, Tetsuo Shoji, Ryusuke Kakiya, Yoshihiro Tsujimoto, Tsutomu Tabata, Eiji Ishimura, Tatsuya Nakatani, Takami Miki, Masaaki Inaba  Kidney International  Volume 63, Pages S117-S120 (May 2003) DOI: 10.1046/j.1523-1755.63.s84.30.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan-Meier curves of causes of death from cardiovascular and non-cardiovascular death in relation to non–HDL cholesterol levels in a cohort of 525 hemodialysis patients. The ranges of non–HDL cholesterol in the lowest, middle, and highest tertiles were 1.09 to 2.74 mmol/L (42 to 106 mg/dL), 2.76 to 3.51 mmol/L (107 to 136 mg/dL), and 3.54 to 7.36 mmol/L (137 to 285 mg/dL), respectively. P values were by log-rank test. Kidney International 2003 63, S117-S120DOI: (10.1046/j.1523-1755.63.s84.30.x) Copyright © 2003 International Society of Nephrology Terms and Conditions